Xeloda(R)-Oxaliplatin Combination (XELOX) Shown To Be More Effective Than Standard Chemotherapy Regimen In Adjuvant Colon Cancer

July 20, 2009 by Admin · Leave a Comment
Filed under: Cancer 

Genentech, Inc. announced that an international Phase III study demonstrated that oral Xeloda® plus oxaliplatin (XELOX) is superior to a commonly used intravenous chemotherapy, 5-FU/LV (infused 5-fluorouracil plus leucovorin), in increasing the time people with adjuvant colon cancer lived without their cancer returning when given immediately after surgery. The data show those who participated in the study and took XELOX immediately after surgery lived longer without their cancer being detectable than those who took intravenous 5U/LV. No new adverse events related to Xeloda were observed in the study.

Data from the trial will be submitted for presentation at upcoming international scientific meetings. Read more

Tags: , , , , ,